Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 14/20 | 0.51 |
| ▸ | MEF2D | Q14814 | 12/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410977 | 1.00 | HDAC4 (0.51) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL19723095 | 0.93 | HDAC1 (0.51) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL1411193 | 0.93 | HDAC1 (0.51) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL1411190 | 0.93 | HDAC1 (0.51) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL1411557 | 0.90 | HDAC3 (0.48) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL1411564 | 0.90 | HDAC3 (0.48) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL1410711 | 0.90 | HDAC3 (0.48) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL1410714 | 0.90 | HDAC3 (0.48) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL19217052 | 0.82 | HDAC4 (0.55) | HDAC4MEF2DHDAC3HDAC1HDAC8 | |
| SCHEMBL8191928 | 0.82 | HDAC4 (0.55) | HDAC4MEF2DHDAC3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323531-A1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-10-30 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8637547-B2 | Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases | CHROMA THERAPEUTICS LTD. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323531-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC4 6/4885MEF2D 525/4885HDAC3 2/4885 |
| US-20100010010-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC4 6/4885MEF2D 527/4885HDAC3 2/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | HDAC4 4/4885MEF2D 226/4885HDAC3 5/4885 |
| US-20130197042-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC4 6/4885MEF2D 525/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.